{"id":"NCT00281658","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2","officialTitle":"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination With Paclitaxel Versus Paclitaxel Plus Placebo in Subjects With ErbB2 Amplified Metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01-02","primaryCompletion":"2010-06-18","completion":"2021-11-23","firstPosted":"2006-01-25","resultsPosted":"2011-06-01","lastUpdate":"2023-02-10"},"enrollment":444,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Neoplasms, Breast"],"interventions":[{"type":"DRUG","name":"Lapatinib (GW572016) oral tablets","otherNames":[]},{"type":"DRUG","name":"Paclitaxel infusion","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Paclitaxel and Lapatinib (Blinded)","type":"EXPERIMENTAL"},{"label":"Paclitaxel and Placebo (Blinded)","type":"ACTIVE_COMPARATOR"},{"label":"Open Label - Monotherapy (Extension Phase)","type":"OTHER"},{"label":"Open Label - Combination Therapy (Extension Phase)","type":"OTHER"}],"summary":"This was a randomized, double-blind, placebo-controlled, multicenter, Phase III study to evaluate and compare the efficacy and safety of Lapatinib + Paclitaxel versus Placebo + Paclitaxel in men and women with ErbB2 amplified metastatic (Stage IV) breast cancer who had not received prior therapy for metastatic disease.","primaryOutcome":{"measure":"Overall Survival (OS) at 53 Months","timeFrame":"From date of randomization until date of death from any cause, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)","effectByArm":[{"arm":"Lapatinib 1500 mg + Paclitaxel","deltaMin":27.8,"sd":null},{"arm":"Placebo + Paclitaxel","deltaMin":20.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0062"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":17,"exclusionCount":18},"locations":{"siteCount":54,"countries":["Brazil","China","Hong Kong","Pakistan","Peru","Russia","Thailand","Ukraine"]},"refs":{"pmids":["25056500","23509322"],"seeAlso":["https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17997"]},"adverseEventsSummary":{"seriousAny":{"events":67,"n":222},"commonTop":["Diarrhoea","Neutropenia","Alopecia","Rash","Leukopenia"]}}